Ling Zhian, Li Ruolin
Department of Emergency, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region - China.
Int J Biol Markers. 2014 Jun 25;29(2):e99-e111. doi: 10.5301/jbm.5000054.
For several years S100A4 has been implicated in tumor progression and prognosis. However, the prognostic value of S100A4 overexpression in patients with gastric cancer remains unknown. Therefore, we performed a meta-analysis to assess the relationship between S100A4 overexpression and clinical outcome of gastric cancer.
Candidate studies were searched from PubMed, Embase, Cochrane Library, and ISI Web of Science. We included studies that evaluated the prognostic value of S100A4 expression in gastric cancer patients with regard to survival and a series of clinicopathological parameters. The pooled hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CI) were used to estimate the effects. Ten studies, all from Asia, were included in the meta-analysis. The pooled analysis showed that S100A4 overexpression was significantly associated with worse overall survival (OS) (HR=1.86, 95% CI: 1.45-2.38, p<0.00001) without heterogeneity in the data (I2=43.6%, p=0.131). Furthermore, our results showed that S100A4 overexpression was significantly correlated with some clinicopathological parameters such as tumor grade, stage, metastasis, invasion, and relapse.
The results of our meta-analysis indicate that S100A4 overexpression correlates with more adverse clinical features and a poor prognosis of gastric cancer patients in Asia, thus suggesting that S100A4 could be a useful marker to evaluate progression and prognosis of Asian gastric cancer patients. More studies from Western countries with a larger number of tumors and standardized methods are required before significant conclusions can be drawn.
多年来，S100A4一直被认为与肿瘤进展和预后有关。然而，S100A4过表达在胃癌患者中的预后价值仍不清楚。因此，我们进行了一项荟萃分析，以评估S100A4过表达与胃癌临床结局之间的关系。
从PubMed、Embase、Cochrane图书馆和ISI科学网检索候选研究。我们纳入了评估S100A4表达在胃癌患者生存及一系列临床病理参数方面预后价值的研究。采用合并风险比（HR）和比值比（OR）及95%置信区间（CI）来估计效应。荟萃分析纳入了全部来自亚洲的10项研究。合并分析显示，S100A4过表达与较差的总生存期（OS）显著相关（HR=1.86，95%CI：1.45-2.38，p<0.00001），数据无异质性（I2=43.6%，p=0.131）。此外，我们的结果表明，S100A4过表达与一些临床病理参数显著相关，如肿瘤分级、分期、转移、侵袭和复发。
我们的荟萃分析结果表明，S100A4过表达与亚洲胃癌患者更差的临床特征和不良预后相关，因此提示S100A4可能是评估亚洲胃癌患者病情进展和预后的有用标志物。在得出有意义的结论之前，需要更多来自西方国家、肿瘤数量更多且方法标准化的研究。
